Cathy Tie, a New York-based serial biotech entrepreneur, has launched Origin Genomics, a privately funded research company dedicated to precision germline gene correction for severe inherited diseases. The company, which follows the conclusion of Tie’s earlier venture Manhattan Genomics, will conduct its work exclusively in the United States under independent institutional review board oversight and in compliance with applicable federal and state regulations. Origin Genomics has also disclosed an intent to offer Mitochondrial Replacement Therapy in the United States, contingent on the passage of federal or state legislation authorising the procedure.

Why launching a germline editing company in the US is a deliberate regulatory calculation

The decision to anchor the company’s operations in the United States rather than in jurisdictions with more permissive frameworks is analytically significant. Under current federal law, germline editing in human embryos cannot be performed using federal funds, and annual congressional budget riders have since 2016 effectively blocked the FDA from reviewing investigational new drug applications involving heritable human genome modifications. What federal law does not prohibit is privately funded, non-clinical laboratory research on germline editing. Origin Genomics appears to be positioning itself in precisely this space: conducting preclinical research under IRB oversight while the legal and regulatory architecture around clinical germline work remains unresolved. This is not a peripheral regulatory manoeuvre. It is a deliberate signal that a credible US-based pathway may be achievable, and that building within existing oversight structures is preferable to operating offshore or in a regulatory grey zone.

The broader US gene therapy regulatory environment has shifted considerably in the past eighteen months. In February 2026, the FDA unveiled a draft guidance framework for a so-called plausible mechanism pathway, designed to accelerate approvals for bespoke gene editing therapies targeting rare diseases with well-characterised genetic causes. While this pathway addresses somatic therapies rather than germline applications, it reflects a regulatory philosophy that is increasingly willing to move faster where underlying biological mechanisms are clear and unmet need is severe. For a company like Origin Genomics, which has explicitly framed its disease targeting around well-characterised nuclear DNA mutations, that philosophical alignment with the FDA’s current direction is not incidental.

What editing fidelity, mosaicism, and off-target work actually means in early embryos

The Origin Genomics research roadmap centres on three technical challenges: improving editing fidelity, reducing mosaicism, and conducting rigorous off-target analysis in early embryonic contexts. These are precisely the unsolved problems that have prevented germline editing from advancing toward clinical consideration in any jurisdiction. Mosaicism, in which only a subset of embryonic cells carry the intended edit, remains one of the most persistent obstacles to predictable germline outcomes. If editing efficiency is uneven across the cells of a developing embryo, some cells will carry the correction while others will not, potentially creating unpredictable downstream effects that could be heritable. This is not a problem that precision of the editing tool alone can resolve; it is also a delivery timing and embryological challenge that requires deep collaboration between molecular biology and reproductive medicine.

Off-target editing in embryonic cells is a separate and compounding concern. Unlike somatic editing, where off-target modifications affect only the treated individual and are not passed to future generations, germline edits that introduce unintended changes to non-target genomic regions could propagate across subsequent generations before consequences become apparent. The field has made considerable progress in characterising off-target rates using base editing and prime editing, both of which offer narrower editing windows and better specificity than the original CRISPR-Cas9 system. Origin Genomics has not disclosed which editing modalities it intends to use, but the company’s implied preference for newer, higher-precision tools is consistent with the broader trajectory of private-sector germline research globally. The company’s founder previously described Manhattan Genomics as exploring these next-generation tools in late 2025 commentary reviewed by industry observers.

How the MRT ambition differs from the nuclear gene correction work and what it requires

Origin Genomics has separated its two core research areas in both scientific and regulatory terms, and that distinction matters. Mitochondrial Replacement Therapy involves replacing an affected mother’s mitochondria with those of a healthy donor, typically through maternal spindle transfer or pronuclear transfer, as part of an IVF procedure. Because it substitutes rather than edits DNA, MRT is scientifically distinct from CRISPR-based germline correction, and its ethical and safety profile is arguably more established. The United Kingdom has offered a licensed MRT pathway since 2017, and as of mid-2025, twenty-two patients had participated in the British programme. Australia passed legislation permitting MRT under a specified licence framework in 2022, with its first clinical trial projected for late 2026.

In the United States, MRT remains blocked at the clinical level by a budget rider that has been attached to annual FDA appropriations since 2016, which prevents the agency from using funds to review any IND application involving heritable human genome modification. This is a congressional spending restriction, not a statutory prohibition, and Origin Genomics has explicitly noted its awareness that state-level regulatory initiatives may provide an alternative pathway. This is a plausible but narrow channel. Any state-level authorisation would need to navigate the FDA’s assertion of regulatory authority over reproductive cells intended for transfer into a human recipient, as the agency has previously issued advisory guidance on exactly this point. Regulatory watchers note that the interplay between a potential state-level MRT framework and federal oversight mechanisms is among the most legally untested areas in the US reproductive medicine landscape.

What the IRB-first model reveals about the company’s compliance strategy

The emphasis on independent IRB oversight as the primary governance framework at launch is worth examining analytically. For non-clinical, privately funded research involving human embryos, IRB oversight is not federally mandated in the same way it is for research receiving federal funding. Institutions routinely establish voluntary oversight, and many follow the International Society for Stem Cell Research guidelines, which recommend IRB-equivalent review for virtually all human embryo research regardless of funding source. Origin Genomics’ proactive invocation of IRB oversight positions the company as choosing a higher standard than current law requires, which is both an ethical statement and a strategic one. It signals to regulators, institutional partners, and prospective collaborators that the company intends to operate within frameworks that would survive scrutiny if and when federal or state policy evolves.

The company has also disclosed that its team includes a policy advisor who contributed to state-level regulatory changes enabling experimental therapies, alongside gene editing and embryology specialists and academic professors. The combination of technical depth and policy expertise is deliberately structured to address the argument that germline research in the United States has historically foundered not on science but on regulatory unpreparedness. Whether that team composition is sufficient to navigate a policy environment that has shown little momentum toward federal germline reform remains an open question, and clinicians tracking the field will be watching whether Origin Genomics can translate its compliance architecture into tangible institutional partnerships.

Risks and unresolved questions that the launch announcement does not address

Several substantive questions remain open. The company has not identified its initial disease targets, the specific editing modalities under development, its funding structure, or its preclinical timeline. The absence of disease target disclosure is understandable at a research-stage company, but it also means that independent assessment of the scientific rationale is not yet possible. Choosing the wrong initial disease targets, specifically those where heterozygous carriers face limited penetrance or where alternative somatic approaches are already advancing in the clinic, would undermine the case for germline intervention before any regulatory conversation begins.

The American Society of Gene and Cell Therapy has stated explicitly that germline editing and the implantation of gene-edited embryos are not ready for human use under current scientific and regulatory conditions, and that any announcements of such studies are compromised ethically and scientifically. This is the baseline position of the leading US professional society in the field, and it represents a significant headwind for any company seeking institutional partnerships or academic collaborations within the United States. Origin Genomics will need to demonstrate that its preclinical programme can produce data sufficient to move that scientific consensus, which is a higher evidentiary bar than the company’s current announcement addresses. The shadow of He Jiankui’s 2018 gene-edited babies experiment, which resulted in criminal prosecution and broad international condemnation, continues to shape how both scientists and regulators assess announcements in this space, regardless of the legitimacy of the underlying research framework.

What regulators and clinicians are likely to watch as this programme develops

Industry observers suggest that the near-term indicators of Origin Genomics’ credibility will not be clinical milestones but scientific and institutional ones. Publication of preclinical data in peer-reviewed journals, the specific academic affiliations of the research team, and the extent to which the company engages formal regulatory pre-consultation with the FDA on its research protocols will each signal whether the company is building a foundation capable of withstanding external review. The FDA’s new plausible mechanism pathway applies to somatic therapies and does not extend to germline applications, but the broader regulatory culture it reflects, one that is willing to evaluate therapies based on well-characterised biological mechanisms rather than solely on large-scale clinical datasets, creates a context in which a well-structured germline research programme could find more receptive interlocutors within the agency than at any prior point in the past decade.

For mitochondrial disease physicians, the MRT strand of Origin Genomics’ programme will generate more immediate interest than the nuclear gene correction work, given the more established safety profile of the technique internationally and the fact that approximately 800 US births annually involve women at risk of transmitting faulty mitochondrial DNA. The gap between that patient population and the complete absence of a US clinical pathway for MRT is one that legislators and reproductive medicine specialists have highlighted repeatedly since the 2016 appropriations rider came into force. Whether Origin Genomics can serve as a credible organisational vehicle to advance that policy conversation, rather than simply conducting basic research in its shadow, is the question that will ultimately define the company’s strategic significance.

  base editing, biotech startups, Cathy Tie, CRISPR, FDA gene therapy, gene therapy, germline gene editing, heritable genome editing, IRB oversight, Manhattan Genomics, mitochondrial replacement therapy, MRT, Origin Genomics, prime editing, rare inherited diseases, reproductive medicine